Authors' recommendations: In heart failure (HF) associated to remodeling and myocardial necrosis in acute myocardial infarction, evidence of moderate quality shows that stem cell therapy (SCT) does not decrease long term incidence or complications. In HF secondary to chronic ischemic heart disease, evidence of low quality highlights a potential clinical benefit associated to SCT in terms of mortality and re-hospitalization, while evidence of moderate quality shows a mild improvement in the ejection fraction and functional class, although not clinically significant. In non-ischemic HF, low quality evidence shows that SCT is associated with a slight improvement in ejection fraction, although not clinically significant. The clinical practice guidelines and the consensus of experts identified consider it necessary to continue investigating the role of SCT in preventing and treating ischemic and non-ischemic HF. In Argentina, INCUCAI (Instituto Nacional Central Único Coordinador de Ablación e Implante, National Unique Central Institute Coordinating Ablation and Implant) does not include SCT for the treatment of HF secondary to ischemic or non-ischemic heart disease. The coverage policies identified consider TCM as experimental for the treatment of HF associated to ischemic and non-ischemic heart disease.

Project Status: Completed

Year Published: 2016

URL for published report: www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)